CGTX Stock Forecast: Cognition Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Cognition Therapeutics, Inc. is $3. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 47 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Cognition Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (81): Analysts have, on balance, been raising their forecasts.
Volatility (13): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
CGTX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CGTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 Nov 2026 | HC Wainwright & Co. | Reiterates | Buy | $3.00 |
| 27 Mar 2026 | Chardan Capital | Maintains | Buy | $4.00 |
| 4 Dec 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 21 Nov 2025 | B. Riley Securities | Reiterates | Buy | — |
| 19 Nov 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 Aug 2025 | Chardan Capital | Maintains | Buy | — |
| 26 June 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 May 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 May 2025 | Chardan Capital | Maintains | Buy | — |
| 24 Mar 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 21 Mar 2025 | Chardan Capital | Maintains | Buy | — |
| 26 Feb 2025 | Chardan Capital | Maintains | Buy | — |
| 19 Dec 2024 | B. Riley Securities | Upgrade | Buy | — |
| 19 Dec 2024 | Chardan Capital | Maintains | Buy | — |
| 19 Dec 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 27 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Nov 2024 | Chardan Capital | Maintains | Buy | — |
| 4 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 31 Oct 2024 | Chardan Capital | Maintains | Buy | — |
| 12 Aug 2024 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CGTX.
This page is one stock. Monday covers all of them.
CGTX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
CGTX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Cognition Therapeutics, Inc. returned −56.2% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
CGTX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 1.9×
- EV / EBITDA
- —
Cheaper than 46% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −48.6%
- Return on assets
- −60.1%
- Dividend yield
- —
Higher than 22% of US stocks
Higher than 6% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Cognition Therapeutics, Inc. has a market value of $55.3M and an enterprise value of $25.1M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$16.8M.
Free cash flow in the twelve months to 30 June 2026: −$17.7M.
Cognition Therapeutics, Inc. employs 14 people.
Data provided by Twelve Data
CGTX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at CGTX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Cognition Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about CGTX
What is the CGTX stock price forecast for 2026-2027?
The median 12-month analyst price target for Cognition Therapeutics, Inc. is $3, with estimates ranging from $3 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is CGTX stock a buy right now?
Of the 2 analysts covering Cognition Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cognition Therapeutics, Inc. 47 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank CGTX?
As at 21 Nov 2026, Cognition Therapeutics, Inc. ranks 47 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (81 of 100).
Will CGTX stock go up?
No one can know that. What the data says: the median 12-month target from 2 analysts is $3, and Ticker Nerd's factor model ranks Cognition Therapeutics, Inc. 47 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the CGTX stock forecast for 2030?
No analyst covering Cognition Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CGTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $4 over the next 12 months.
How has CGTX stock performed over the past year?
Cognition Therapeutics, Inc. returned -56.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Cognition Therapeutics, Inc. do?
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for age-related degenerative diseases affecting the central nervous system and the retina. Its lead program centers on zervimesine (CT1812), an oral candidate designed to protect neuronal synapses and modulate disease-related protein interactions.
About Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for age-related degenerative diseases affecting the central nervous system and the retina. Its lead program centers on zervimesine (CT1812), an oral candidate designed to protect neuronal synapses and modulate disease-related protein interactions. The company is evaluating this candidate across multiple neuroscience and neuro-ophthalmology settings, including Alzheimer’s disease, mild cognitive impairment, dementia with Lewy bodies, and geographic atrophy associated with dry age-related macular degeneration. Cognition Therapeutics combines mechanistic research with translational and clinical development to address disorders linked to synaptic dysfunction and cellular stress. Headquartered in Purchase, New York, the company plays a specialized role in the biotech market as a developer of targeted treatments for complex neurodegenerative and retinal conditions.
CEO Ms. Lisa Ricciardi · 14 employees · United States · https://www.cogrx.com